Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer

Purpose: Magnetic resonance imaging-guided transurethral ultrasound ablation uses directional thermal ultrasound under magnetic resonance imaging thermometry feedback control for prostatic ablation. We report 12-month outcomes from a prospective multicenter trial (TACT). Materials and methods: A tot...

Descripción completa

Detalles Bibliográficos
Autores: Klotz, Laurence, Pavlovich, Christian P., Chin, Joseph, Hatiboglu, Gencay, Koch, Michael, Penson, David, Raman, Steven, Oto, Aytekin, Fütterer, Jurgen, Serrallach, Marc, Relle, James, Lotan, Yair, Heidenreich, Axel, Bonekamp, David, Haider, Masoom, Tirkes, Temel, Arora, Sandeep, Macura, Katarzyna J., Costa, Daniel N., Persigehl, Thorsten, Pantuck, Allan J., Bomers, Joyce, Burtnyk, Mathieu, Staruch, Robert, Eggener, Scott
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/178676
Acceso en línea:https://hdl.handle.net/2445/178676
Access Level:acceso abierto
Palabra clave:Càncer de pròstata
Radioteràpia
Prostate cancer
Radiotherapy
Imatges per ressonància magnètica
Magnetic resonance imaging
id ES_2d2ceb4ba8488a409c58d7101dfe4d2b
oai_identifier_str oai:diposit.ub.edu:2445/178676
network_acronym_str ES
network_name_str España
repository_id_str
spelling Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate CancerKlotz, LaurencePavlovich, Christian P.Chin, JosephHatiboglu, GencayKoch, MichaelPenson, DavidRaman, StevenOto, AytekinFütterer, JurgenSerrallach, MarcRelle, JamesLotan, YairHeidenreich, AxelBonekamp, DavidHaider, MasoomTirkes, TemelArora, SandeepMacura, Katarzyna J.Costa, Daniel N.Persigehl, ThorstenPantuck, Allan J.Bomers, JoyceBurtnyk, MathieuStaruch, RobertEggener, ScottCàncer de pròstataRadioteràpiaProstate cancerRadiotherapyImatges per ressonància magnèticaMagnetic resonance imagingPurpose: Magnetic resonance imaging-guided transurethral ultrasound ablation uses directional thermal ultrasound under magnetic resonance imaging thermometry feedback control for prostatic ablation. We report 12-month outcomes from a prospective multicenter trial (TACT). Materials and methods: A total of 115 men with favorable to intermediate risk prostate cancer across 13 centers were treated with whole gland ablation sparing the urethra and apical sphincter. The co-primary 12-month endpoints were safety and efficacy. Results: In all, 72 (63%) had grade group 2 and 77 (67%) had NCCN® intermediate risk disease. Median treatment delivery time was 51 minutes with 98% (IQR 95-99) thermal coverage of target volume and spatial ablation precision of ±1.4 mm on magnetic resonance imaging thermometry. Grade 3 adverse events occurred in 9 (8%) men. The primary endpoint (U.S. Food and Drug Administration mandated) of prostate specific antigen reduction ≥75% was achieved in 110 of 115 (96%) with median prostate specific antigen reduction of 95% and nadir of 0.34 ng/ml. Median prostate volume decreased from 37 to 3 cc. Among 68 men with pretreatment grade group 2 disease, 52 (79%) were free of grade group 2 disease on 12-month biopsy. Of 111 men with 12-month biopsy data, 72 (65%) had no evidence of cancer. Erections (International Index of Erectile Function question 2 score 2 or greater) were maintained/regained in 69 of 92 (75%). Multivariate predictors of persistent grade group 2 at 12 months included intraprostatic calcifications at screening, suboptimal magnetic resonance imaging thermal coverage of target volume and a PI-RADS™ 3 or greater lesion at 12-month magnetic resonance imaging (p <0.05). Conclusions: The TACT study of magnetic resonance imaging-guided transurethral ultrasound whole gland ablation in men with localized prostate cancer demonstrated effective tissue ablation and prostate specific antigen reduction with low rates of toxicity and residual disease.Wolters Kluwer Health2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/178676Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1097/JU.0000000000001362Journal of Urology, 2021, vol. 205, num. 3, p. 769-779https://doi.org/10.1097/JU.0000000000001362cc by-nc-nd (c) Klotz et al., 2021http://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1786762026-05-27T06:46:51Z
dc.title.none.fl_str_mv Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
title Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
spellingShingle Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
Klotz, Laurence
Càncer de pròstata
Radioteràpia
Prostate cancer
Radiotherapy
Imatges per ressonància magnètica
Magnetic resonance imaging
title_short Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
title_full Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
title_fullStr Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
title_full_unstemmed Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
title_sort Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
dc.creator.none.fl_str_mv Klotz, Laurence
Pavlovich, Christian P.
Chin, Joseph
Hatiboglu, Gencay
Koch, Michael
Penson, David
Raman, Steven
Oto, Aytekin
Fütterer, Jurgen
Serrallach, Marc
Relle, James
Lotan, Yair
Heidenreich, Axel
Bonekamp, David
Haider, Masoom
Tirkes, Temel
Arora, Sandeep
Macura, Katarzyna J.
Costa, Daniel N.
Persigehl, Thorsten
Pantuck, Allan J.
Bomers, Joyce
Burtnyk, Mathieu
Staruch, Robert
Eggener, Scott
author Klotz, Laurence
author_facet Klotz, Laurence
Pavlovich, Christian P.
Chin, Joseph
Hatiboglu, Gencay
Koch, Michael
Penson, David
Raman, Steven
Oto, Aytekin
Fütterer, Jurgen
Serrallach, Marc
Relle, James
Lotan, Yair
Heidenreich, Axel
Bonekamp, David
Haider, Masoom
Tirkes, Temel
Arora, Sandeep
Macura, Katarzyna J.
Costa, Daniel N.
Persigehl, Thorsten
Pantuck, Allan J.
Bomers, Joyce
Burtnyk, Mathieu
Staruch, Robert
Eggener, Scott
author_role author
author2 Pavlovich, Christian P.
Chin, Joseph
Hatiboglu, Gencay
Koch, Michael
Penson, David
Raman, Steven
Oto, Aytekin
Fütterer, Jurgen
Serrallach, Marc
Relle, James
Lotan, Yair
Heidenreich, Axel
Bonekamp, David
Haider, Masoom
Tirkes, Temel
Arora, Sandeep
Macura, Katarzyna J.
Costa, Daniel N.
Persigehl, Thorsten
Pantuck, Allan J.
Bomers, Joyce
Burtnyk, Mathieu
Staruch, Robert
Eggener, Scott
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Càncer de pròstata
Radioteràpia
Prostate cancer
Radiotherapy
Imatges per ressonància magnètica
Magnetic resonance imaging
topic Càncer de pròstata
Radioteràpia
Prostate cancer
Radiotherapy
Imatges per ressonància magnètica
Magnetic resonance imaging
description Purpose: Magnetic resonance imaging-guided transurethral ultrasound ablation uses directional thermal ultrasound under magnetic resonance imaging thermometry feedback control for prostatic ablation. We report 12-month outcomes from a prospective multicenter trial (TACT). Materials and methods: A total of 115 men with favorable to intermediate risk prostate cancer across 13 centers were treated with whole gland ablation sparing the urethra and apical sphincter. The co-primary 12-month endpoints were safety and efficacy. Results: In all, 72 (63%) had grade group 2 and 77 (67%) had NCCN® intermediate risk disease. Median treatment delivery time was 51 minutes with 98% (IQR 95-99) thermal coverage of target volume and spatial ablation precision of ±1.4 mm on magnetic resonance imaging thermometry. Grade 3 adverse events occurred in 9 (8%) men. The primary endpoint (U.S. Food and Drug Administration mandated) of prostate specific antigen reduction ≥75% was achieved in 110 of 115 (96%) with median prostate specific antigen reduction of 95% and nadir of 0.34 ng/ml. Median prostate volume decreased from 37 to 3 cc. Among 68 men with pretreatment grade group 2 disease, 52 (79%) were free of grade group 2 disease on 12-month biopsy. Of 111 men with 12-month biopsy data, 72 (65%) had no evidence of cancer. Erections (International Index of Erectile Function question 2 score 2 or greater) were maintained/regained in 69 of 92 (75%). Multivariate predictors of persistent grade group 2 at 12 months included intraprostatic calcifications at screening, suboptimal magnetic resonance imaging thermal coverage of target volume and a PI-RADS™ 3 or greater lesion at 12-month magnetic resonance imaging (p <0.05). Conclusions: The TACT study of magnetic resonance imaging-guided transurethral ultrasound whole gland ablation in men with localized prostate cancer demonstrated effective tissue ablation and prostate specific antigen reduction with low rates of toxicity and residual disease.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/178676
url https://hdl.handle.net/2445/178676
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1097/JU.0000000000001362
Journal of Urology, 2021, vol. 205, num. 3, p. 769-779
https://doi.org/10.1097/JU.0000000000001362
dc.rights.none.fl_str_mv cc by-nc-nd (c) Klotz et al., 2021
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by-nc-nd (c) Klotz et al., 2021
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wolters Kluwer Health
publisher.none.fl_str_mv Wolters Kluwer Health
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405297355784192
score 15,300719

Similares en LA Referencia